PRAnnounced Capital and Business Alliance with MEDIPAL HOLDINGS
PRAnnounced Capital Alliance with ITOCHU CHEMICAL FRONTIER
OtherKay Deguchi was appointed as Independent Director
MediaLinks of Keiichi Fukuda’ interviews were posted at CEO Profile.
PRHeartseed raises $26 Million in Series B Funding
OtherAkira Fujiyoshi was appointed as External Auditor
Co-DevelopmentOur research partner, Keio Univ. applied for permission to conduct FIH of iPSC-derived CMs transplant to patients with DCM.
OtherKikuo Yasui was appointed as COO
OtherTomoyuki Kikugawa was appointed as External Auditor (full-time)
PRHeartseed Inc. was selected as one of the subsidy program of Japan Agency for Medical Research and Development (AMED), supporting Research Project for Practical Applications of Regenerative Medicine